慢性乙型肝炎和原发性肝癌患者体内人腺病毒5型、26型及黑猩猩腺病毒68型中和抗体的流行率

目的:调查慢性乙型病毒性肝炎(CHB)和原发性肝癌(PLC)患者体内人腺病毒5型(Ad Hu5)、26型(Ad Hu26)和黑猩猩腺病毒68型(Ad C68)中和抗体的流行率,为这2种疾病开发安全有效的生物治疗载体提供依据。方法:我们收集196份CHB患者的血清和193份PLC患者的血清,通过腺病毒中和实验检测血清中Ad Hu5、Ad Hu26和Ad C68的中和抗体。结果:在CHB患者中Ad Hu5、Ad Hu26和Ad C68中和抗体的阳性率分别为84.7%、58.2%及39.8%;在PLC患者中Ad Hu5、Ad Hu26和Ad C68中和抗体的阳性率分别为75.1%、66.8%及32.1%。结论:本次实验显示3种腺病毒中和抗体的流行率和抗体滴度都以Ad C68的最低,故其作为CHB和PLC的生物治疗载体较Ad Hu5与Ad Hu26具有优势。

Seroprevalence of neutralizing antibodies to human adenovirus type 5, human adenovirus type 26 and chimpanzee adenovirus type 68 in patients with chronic hepatitis B and patients with primary liver cancer

AIM: To investigate the seroprevalence of neutralizing antibodies to human adenovirus type 5 (AdHu5), human adenovirus type 26 (AdHu26) and chimpanzee adenovirus type 68 (AdC68) in the patients with chronic hepatitis B (CHB) and the patients with primary liver cancer (PLC), and to provide guidance for developing safe and effective biotherapy vectors against CHB and PLC. METHODS: The blood samples from 196 patients with CHB and 193 patients with PLC were examined to assess the presence of neutralizing antibodies against AdHu5, AdHu26 and AdC68 by adenovirus neutralization assays. RESULTS: The seroprevalence rates of neutralizing antibodies to AdHu5, AdHu26 and AdC68 in the CHB patients were 84.7%, 58.2% and 39.8%, respectively. Among the patients with PLC, the prevalence rates of neutralizing antibodies were as follows: AdHu5, 75.1%; AdHu26, 66.8%; AdC68, 32.1%. CONCLUSION: The prevalence rates and titers of neutralizing antibodies against AdC68 were the lowest among the 3 adenoviruses. Therefore, AdC68 serves as more suitable biological therapy vectors for CHB and PLC than AdHu5 and AdHu26.